IPSOGEN to Present Two Studies on the Genomic Grade Test at ASCO 2011 in Chicago, Ill, USA

MARSEILLE, France, May 31, 2011 /PRNewswire-FirstCall/ — IPSOGEN SA
(Alternext: ALIPS) today announces that two studies on the Genomic Grade test
will be presented at the American Society for Clinical Oncology (ASCO) Annual
Meeting, that will take place June 3-7, 2011, in Chicago, Ill, USA. The
Genomic Grade test (GG), a multi-gene expression test, improves tumor
grading, long term prognostication, and consequently treatment decisions for
women with early invasive hormone receptor positive breast cancer.

The first study has been run prospectively with a network of 8 Belgian
breast cancer centres. The second study, focusing on lobular carcinoma,
results from a collaboration with Institut Jules Bordet, and St Luc Hospital,
Belgium, and Institut Paoli-Calmettes, France. Both studies, developed in
different settings, provide additional evidence for the added value of the
Genomic Grade test for tumor grading and, consequently, long term prognosis
evaluation.

Poster Presentation: Genomic grade: Feasibility in routine practice and
influence on treatment decision in early breast cancer (Abstract #606)

– Lead Author: O. Metzger, Be

– June 6, 1:00 pm to 5:00 pm

– Location: McCormick Place Hall A

Poster Presentation and Discussion: Use of genomic grade index to improve
tumor grading of invasive lobular breast carcinoma (Abstract #535)

    - Lead Author: D. Fumagalli, Be
    - June 7, 8:00 am to 12:00 pm
    - Discussion Time: Tuesday June 7, 11:30 AM to 12:30 PM
    - Location: McCormick Place E450a

Both abstracts are available on ASCO’s website, http://www.asco.org or
http://www.abstract.asco.org.

About Genomic Grade

The value of tumor grade as one of the key drivers for long term
prognosis of hormone receptor positive early invasive breast cancer has been
widely documented over the last decade and tumor grade is part of all current
treatment guidelines and decision algorithms. However, assessment of tumor
grade, measured to date by histology, suffers two limitations: 1/variability
of assessment across pathology labs, and 2/presence of an intermediate
category, histologic grade 2, which can represent as much as 50% of tumors
and has a limited informative power for treatment decision making.

The Genomic Grade is addressing these 2 limitations. Proliferation genes
are the main component of the selected gene signature. The added value of
Genomic Grade to identify high and low grade tumors, esp. in histologic grade
2 tumors, has been documented on 3 000 cases. Moreover, Genomic Grade is able
to separate Luminal A and Luminal B tumors.

Genomic Grade is currently available in Europe as MapQuant(TM), an
Affymetrix micro-array based assay. A PCR version of the test, adapted to
formalin fixed-parafin embedded specimens, is under development and should be
available end 2011.

About Invasive Lobular Carcinoma

Invasive lobular carcinoma, which represents approx. 10% of invasive
breast carcinoma, is the second most common histologic type after ductal
carcinoma. Its management and treatment modalities are similar to those of
ductal carcinoma.

However, because of the specific abnormalities characteristising lobular
carcinoma cells, it is particularly difficult to reliably measure tumor grade
with the standard histologic tools. Moreover, up to 80% of lobular carcinoma
are classified as histologic grade 2, an intermediate grade category of
limited informative value. It is therefore difficult to apply the
well-validated treatment decision algorithms -most of them incorporating
tumor grade- for this category of breast carcinoma.

About IPSOGEN

IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests
that help to map diseases and guide patients and oncologists’ decisions along
their therapeutic path.

With more than 80 tests already used routinely worldwide for the
diagnosis, prognosis and follow-up of thousands of patients with leukemia,
IPSOGEN is now targeting breast cancer with the aim of providing currently
inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships,
and by its multidisciplinary team in France and the USA, IPSOGEN intends to
become a world leader in the molecular profiling of cancers, and to continue
the development and promotion of best-in-class diagnostic references that
have a significant impact on patients, medical professionals and society.

The company headquartered in Marseille, France has a subsidiary in the
USA.

    For further information, visit http://www.ipsogen.com

    Contacts

    IPSOGEN
    Vincent Fert
    CEO
    Tel : +33(0)4-9129-3090
    fert@ipsogen.com

    Helene Peyro-Saint-Paul
    CMO
    Tel : +33(0)4-9129-3090
    peyro-saint-paul@ipsogen.com

    Pascale Boissel
    CFO
    Tel : +33(0)4-9129-3090
    pascale.boissel@ipsogen.com

    ATCG Press                   NewCap.
    Corporate and Product        Financial communication and
    Information                  Investor relations
    Marielle Bricman             Axelle Vuillermet & Pierre Laurent
    Tel : +33(0)4-9125-0785      Tel : +33(0)1-44-71-94-93
    ipsogen@atcg-partners.com    ipsogen@newcap.fr

SOURCE Ipsogen SA